XNCR

XencorF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$16.00

+42.7% vs current

Most likely

Base case

50%

Probability

Target price

$11.50

+2.6% vs current

B-

Bear case

25%

Probability

Target price

$8.00

-28.6% vs current

AI sentiment snapshot

Latest data as of 2026-05-16

AI commentary

Primary-source tone is operationally constructive, but the earnings follow-up is not cleanly bullish. The stock closed at $12.85 on May 5, 2026, before the May 6 release, and at $11.22 on May 15, 2026, suggesting a negative post-print drift rather than an immediate relief rally. Checked secondary earnings coverage also pointed to a miss versus expectations, while clearly attributable post-print analyst target revisions were limited in the sources reviewed, so confidence should stay moderate at best.

RankAlpha Sentiment Codex - 2026-05-16

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalystPost-Q1 digestion of royalty reset and runwayHigh impact

Q1 results showed revenue fell to $4.5 million, including a one-time $6.6 million reduction tied to disputed U.S. Ultomiris royalties, while management still guided to $380-$400 million of year-end 2026 cash and runway into mid-2028 [#8-K-2026-05-06]. Near-term sentiment likely depends on whether investors view the royalty dispute as ring-fenced versus a broader cash-flow reset.

2026-10-15eventXmAb819 ccRCC expansion-cohort data in 2H26High impact

Management said XmAb819 expansion-cohort results in clear cell renal cell carcinoma are planned for a medical conference in the second half of 2026 and are intended to support a first pivotal study in 2027 [#8-K-2026-05-06]. This is one of the cleaner program-specific upside hooks in the current packet.

2026-12-31catalystAutoimmune pipeline milestones for XmAb412 and XmAb942High impact

Xencor said XmAb412 remains on track for a first-in-human healthy participant study in 3Q26, while XmAb942 Phase 2b XENITH-UC enrollment supports a blinded interim analysis around year-end 2026 and primary-endpoint induction data in 2H27 [#8-K-2026-05-06]. These milestones matter, but the payoff is longer-dated and still clinically binary.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-16 • Updated nightlySource: Internal modelMethodology